Acute liver failure

Baxter Reports First-Quarter 2023 Results

Retrieved on: 
木曜日, 4月 27, 2023
Biotechnology, Managed Care, Medical Supplies, Surgery, Health, Medical Devices, Hospitals, Fitness & Nutrition, Galaxy, DNA, ALF, Agility, Noise, Piperacillin, Fort Robinson breakout, Pump, Baxter, COVID-19, Thrombin, IQ, GAAP, Baxter International, U.S. FDA, Tazobactam, Acute liver failure, Information International, Inc., Hospital, Patient, Generally Accepted Accounting Principles (United States), Injection, Novum, Liver, Growth, CDT, SYR, NYSE, LVP, Cryptocurrency, Fine chemical, Pharmaceutical industry, Management, Security (finance)

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
  • On an adjusted basis, net income attributable to Baxter totaled $297 million, or $0.59 per diluted share, a 37% decrease.
  • Baxter expects to report quarterly performance in line with the new operating model beginning in the second half of 2023.
  • Among recent corporate responsibility highlights, Baxter and the Baxter International Foundation advanced support for disaster relief in response to February’s devastating earthquake in Turkey and Syria.

Global Hepatic Encephalopathy Therapeutics Market Report 2023: Players Include Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline and Pfizer - ResearchAndMarkets.com

Retrieved on: 
水曜日, 4月 19, 2023
Health, Pharmaceutical, Myenteric plexus, Seizure, Rifaximin, Hepatitis, Liver function tests, Therapy, Prevalence, Probiotic, Liver, Liver disease, Public, Anxiety, NORD, USFDA, Hepatic encephalopathy, Lactulose, Nutrient, Brain, National Organ Transplant Act of 1984, Thiamine, Acute liver failure, Plasma, Rare, Acetic acid, Patient, Ammonia, Lethargy, Confusion, Diagnosis, Personality, Cirrhosis, Disease, Vaccine, Dietary supplement

If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis.

Key Points: 
  • If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis.
  • Hepatic encephalopathy is categorized into 3 types Type A (acute liver failure), Type B (portal systemic bypass without liver disease), and Type C (liver cirrhosis).
  • The clinical manifestation associated with hepatic encephalopathy is confusion, anxiety, lethargy, seizures, confused speech, personality changes, and poor body movements.
  • In 2010 the USFDA approved Rifaximin for the treatment of hepatic encephalopathy by acting on the microorganisms in the intestinal tract producing ammonia.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO

Retrieved on: 
日曜日, 4月 16, 2023
LLP, CMC, Chemistry, Acute liver failure, FDA, Pomerantz, Letter, IND, News, MIRO, Cryptocurrency, Pharmaceutical industry

NEW YORK, April 16, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).

Key Points: 
  • NEW YORK, April 16, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).
  • The investigation concerns whether Miromatrix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The press release further provided that the FDA would provide an official clinical hold letter to Miromatrix within 30 days.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO

Retrieved on: 
日曜日, 4月 9, 2023
LLP, CMC, Chemistry, Acute liver failure, FDA, Pomerantz, Letter, IND, News, MIRO, Cryptocurrency, Pharmaceutical industry

NEW YORK, April 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).

Key Points: 
  • NEW YORK, April 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).
  • The investigation concerns whether Miromatirx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The press release further provided that the FDA would provide an official clinical hold letter to Miromatrix within 30 days.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Miromatrix Reports Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Retrieved on: 
金曜日, 3月 31, 2023
Reprise, Operating cost, IPO, University, Event, Research, Baxter International, Acute liver failure, Patient, Investment, Collection, Average cost, EDEN, FDA, MIRO, Pharmaceutical industry, Cryptocurrency, Video game

Miromatrix had $1.7 million of one-time cash outlays in the first quarter of 2022 related to the build-out of our new headquarters.

Key Points: 
  • Miromatrix had $1.7 million of one-time cash outlays in the first quarter of 2022 related to the build-out of our new headquarters.
  • Licensing revenue for the fourth quarter of 2022 was $930,355, compared to $8,000 in the fourth quarter of 2021.
  • Operating loss for the fourth quarter of 2022 was $7.180 million, compared to $5.465 million in the fourth quarter of 2021.
  • Net loss for the fourth quarter of 2022 was $6.946 million, or $0.33 per share, compared to $5.476 million, or $0.27 per share in the fourth quarter of 2021.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO

Retrieved on: 
月曜日, 2月 20, 2023
LLP, Pomerantz, Acute liver failure, CMC, News, Letter, FDA, Chemistry, MIRO, IND, Cryptocurrency, Pharmaceutical industry

NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).

Key Points: 
  • NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).
  • The investigation concerns whether Miromatrix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The press release further provided that the FDA would provide an official clinical hold letter to Miromatrix within 30 days.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO

Retrieved on: 
水曜日, 2月 15, 2023
LLP, Pomerantz, Acute liver failure, CMC, News, Letter, FDA, Chemistry, MIRO, IND, Cryptocurrency, Pharmaceutical industry

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).

Key Points: 
  • NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).
  • The investigation concerns whether Miromatirx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The press release further provided that the FDA would provide an official clinical hold letter to Miromatrix within 30 days.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

Retrieved on: 
水曜日, 2月 1, 2023
Medical Supplies, Health, Medical Devices, Hospitals, Genetics, Pharmaceutical, Biotechnology, Baxter, ALF, Hospital, Hemofiltration, CRRT, ICU, NYSE, Acute liver failure, Patient, Liver, Food, Drug discovery, Baxter International, Liver failure, FDA, Multimedia, MIRO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Pharmaceutical industry, Medical imaging

Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies.

Key Points: 
  • Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies.
  • As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system.
  • Miromatrix intends to commence a Phase I clinical trial using miroliverELAP to treat patients suffering from ALF, following FDA’s decision that the trial may proceed.
  • “Combining Miromatrix’s pioneering bioengineered organ technology with Baxter’s expertise in critical care delivery and industry-leading PrisMax system has the potential to transform care for ALF patients.”

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO

Retrieved on: 
日曜日, 2月 5, 2023
MIRO, IND, Pomerantz, CMC, LLP, Acute liver failure, FDA, Chemistry, Letter, News, Dietary supplement

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).

Key Points: 
  • NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Miromatrix Medical Inc. (“Miromatrix” or the “Company”) (NASDAQ: MIRO).
  • The investigation concerns whether Miromatrix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • The press release further provided that the FDA would provide an official clinical hold letter to Miromatrix within 30 days.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

Retrieved on: 
水曜日, 2月 1, 2023
MIRO, Liver, Health, Baxter International, Baxter, Food, IND, NYSE, Hospital, EDEN, Acute liver failure, Liver failure, Drug discovery, Hemofiltration, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, ALF, ICU, CRRT, Pharmaceutical industry, Medical imaging

As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system.

Key Points: 
  • As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system.
  • Miromatrix intends to commence a Phase I clinical trial using miroliverELAP to treat patients suffering from ALF, following FDA’s decision that the trial may proceed.
  • “We are excited to be partnering with Baxter to pioneer this next generation innovation in acute care and liver disease.”
    ALF is a serious condition with limited clinical interventions.
  • “Combining Miromatrix’s pioneering bioengineered organ technology with Baxter’s expertise in critical care delivery and industry-leading PrisMax system has the potential to transform care for ALF patients.”